Open-house rebate agreements for Rivaroxaban film-coated tablets excluding 2.5 mg
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rivaroxaban Filmtabletten, ausgenommen in der Wirkstärke 2,5 mg, ATC B01AF01
Opportunity Score
Why this score?
Opportunity
62 / 100
Complexity
58 / 100
Risk factors
The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...
Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Non-exclusive supply/rebate agreement for Rivaroxaban film-coated tablets, excluding 2.5 mg strength.
- Open-house model with identical, non-individually negotiable contract terms.
Show full summary
This is an open-house pharmaceutical supply arrangement by AOK Bayern for Rivaroxaban film-coated tablets excluding the 2.5 mg strength (CPV 33600000). It is explicitly described as non-exclusive and non-negotiated, with contracts offered to all interested pharmaceutical companies that meet the stated suitability requirement. The notice includes electronic and paper submission options via DTVP or by post, with strict monthly cut-off rules for contract start dates. No contract value is stated.
Risks
The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...
Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- Signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
- Signed contract and completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open-house rebate agreements for Rivaroxaban film-coated tablets excluding 2.5 mg
Open-house framework-style supply arrangement for Rivaroxaban film-coated tablets, excluding the 2.5 mg strength, for AOK Bayern. The lot description states that contract documents must be submitted via the communication area in the DTVP portal, not via the offer area. The lot is explicitly open to all interested pharmaceutical companies meeting the suitability requirement; information in the notice indicates a maximum of 999 operators may join.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Rivaroxaban Filmtabletten, ausgenommen in der Wirkstärke 2,5 mg, ATC B01AF01
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 13 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 457937-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
62 / 100
Complexity
58 / 100
Risk factors
The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...
Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications